Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

COVID-2019 immune globulins - Emergent BioSolutions

Next Previous
Drug Profile

COVID-2019 immune globulins - Emergent BioSolutions

Alternative Names: Anti-coronavirus hIVIG - Emergent BioSolutions; Anti-coronavirus hyperimmune intravenous immunoglobulin - Emergent BioSolutions; Anti-SARS-CoV-2 immune globulin intravenous (Human) - Emergent BioSolutions; COVID-HIG - Emergent BioSolutions; NP-028

Latest Information Update: 26 Jun 2026

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Emergent BioSolutions
  • Developer Emergent BioSolutions; National Institute of Allergy and Infectious Diseases; University of Minnesota
  • Class Antivirals; Immunoglobulins; Polyclonal antibodies
  • Mechanism of Action Immunomodulators
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Phase III COVID 2019 infections

Most Recent Events

  • 11 Jun 2026 University of Minnesota suspends the phase III Outpatient Treatment with Anti-Coronavirus Immunoglobulin (OTAC) trial in COVID-2019 infections in USA, Argentina, Australia, Denmark, Malaysia, Mexico, Greece, Peru, Spain, Thailand, Uganda, Ukraine, United Kingdom (IV, Infusion) (NCT04910269)
  • 28 Jan 2025 No recent reports of development identified for phase-I development in COVID-2019-infections(In volunteers) in USA (IM)
  • 28 Jan 2025 No recent reports of development identified for phase-I development in COVID-2019-infections(In volunteers) in USA (SC)

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top